Capricor Therapeutics Inc. (CAPR)
NASDAQ · Healthcare
Capricor Therapeutics Inc. EBITDA 2011–2025
Capricor Therapeutics Inc. annual/quarterly ebitda history and growth rate from 2011 to 2024. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Capricor Therapeutics Inc. ebitda for the quarter ending March 31, 2024 was -9.9 M, a 24.89% increase year-over-year.
- Capricor Therapeutics Inc. ebitda for the twelve months ending March 31, 2024 was -25.1 M, a 80.76% increase year-over-year.
- Capricor Therapeutics Inc. annual ebitda for 2025 was -106.3 M, a 158.28% increase from 2024.
- Capricor Therapeutics Inc. annual ebitda for 2024 was -41.1 M, a 78.79% increase from 2023.
- Capricor Therapeutics Inc. annual ebitda for 2023 was -23.0 M, a 21.11% decrease from 2022.
- Capricor Therapeutics Inc. annual ebitda for 2022 was -29.2 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Capricor Therapeutics Inc. EBITDA — FAQ
Capricor Therapeutics Inc. (CAPR) ebitda over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CAPR's ebitda history?
The chart and table above show Capricor Therapeutics Inc.'s ebitda by year and by quarter, including the growth rate.